MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for ...

The FDA approved a label update for Winrevair to include that it lowers the risk for clinical worsening events in adults with ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...

On October 27, 2025, Merck announced that the FDA approved an expanded label for WINREVAIR (sotatercept-csrk), allowing its ...

Rahway: Merck, known as MSD outside the United States and Canada, has announced that the company has received approval from ...

More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...

The FDA has approved an updated indication for sotatercept-csrk (WINREVAIR), an activin signaling inhibitor, for adults with pulmonary arterial hypertension (PAH) in WHO functional class III or ...

The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...